AlixiaTargeting the Tumor Ecosystem to address cancer drug resistance.

Alixia: Targeting the Tumor Ecosystem

Revolutionizing Cancer Treatment

Alixia is dedicated to addressing cancer drug resistance and improving patients' lives by treating cancers as dynamic ecosystems.

Key Features

• Tumor Ecosystem Disruptors: Lead compounds that disrupt metabolic and inflammatory triggers in cancer and quasi-cancerous cells.
• Integrated Approach: Combining biology, biophysics, computational chemistry, and clinical input to drive therapeutic innovation.
• Broad Impact: Targeting multiple cell types within the tumor microenvironment to collapse tumor ecosystems.

Use Cases

• Cancer Treatment: Effective for relapsed and refractory solid tumors.
• Aging: Addressing neurodegeneration and other age-related diseases.
• Inflammation: Tackling immune dysregulation and chronic inflammatory conditions.

Pricing

Alixia offers a range of therapeutic programs at various stages of preclinical development. Contact us for detailed pricing and collaboration opportunities.

Teams

Our team comprises experienced scientists, clinicians, and drug developers dedicated to transforming medicine. Key members include:

• Olof Mollstedt: Co-founder & Co-CEO, with a background in engineering physics and experience at NASA and Ambryx.
• Helen Chen, Ph.D.: Co-founder & Co-CEO, with over 15 years of biotech experience and a strong background in molecular biochemistry and biophysics.

Join us in our mission to revolutionize cancer treatment and improve patient outcomes.